Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Officially an ILS Resuscitation Council Course Centre

7
March 2018

View Articles

Dr Jorg Taubel attending ACCP in San Diego

5
September 2017

View Articles

DIA, Chicago 2017

23
June 2017

View Articles

Richmond Pharmacology’s New London Bridge unit offers unrivalled access to patient recruitment

28
April 2017

Richmond Pharmacology has been settling into life in its New London Bridge Research Unit.

View Articles

New CRO unit facility welcomes first overnight patients

31
March 2017

Richmond Pharmacology has been busy settling in their first patients at the new London Bridge site.

View Articles

Richmond Pharmacology Opens New London Bridge Site

3
March 2017

This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis.

View Articles

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event